Microvascular Angina - Symptoms, Causes, Treatment & Prevention

Overview

Microvascular angina (MVA), also called cardiac syndrome X or microvascular coronary dysfunction, is a type of chest pain that results from abnormal function of the small coronary vessels (micro‑vessels) rather than a blockage in the larger epicardial arteries. The micro‑vessels are < 0.5 mm in diameter and cannot be visualized on conventional coronary angiography. When they fail to dilate appropriately, the heart muscle may receive insufficient oxygen, producing angina‑like symptoms.

Key points:

• Predominantly affects women (≈ 60‑70 % of diagnosed cases) but can occur in men.
• Typical age of onset: middle‑aged (40‑60 years), though younger patients are reported.
• Prevalence estimates vary because the condition is under‑diagnosed; population‑based studies suggest that 20‑30 % of patients with chest pain and normal coronary arteries have microvascular angina.¹

Symptoms

Symptoms of microvascular angina closely mimic those of classic obstructive coronary artery disease (CAD), but subtle differences can help clinicians suspect MVA.

Typical Chest Pain

• Quality: pressure, heaviness, squeezing, or burning sensation.
• Location: central chest, may radiate to jaw, neck, shoulders, or arms.
• Duration: usually 2–10 minutes, can last longer than typical stable angina.
• Triggers: physical exertion, emotional stress, cold exposure, large meals, or even at rest.
• Relief: often improves with rest or nitroglycerin, but response may be partial.

Atypical or Associated Symptoms

• Shortness of breath (dyspnea) on exertion.
• Fatigue or reduced exercise tolerance.
• Palpitations.
• Feeling of “tightness” or “fullness” in the chest.
• Occasional dizziness or near‑syncope.

Red‑Flag Features that Suggest Alternative Diagnosis

• Chest pain that awakens you from sleep.
• Profound, crushing pain lasting > 30 minutes.
• Associated syncope, sudden loss of consciousness, or severe shortness of breath.

Causes and Risk Factors

Microvascular angina is a multifactorial disease. The exact pathophysiology is still being investigated, but several mechanisms are recognized:

Pathophysiologic Mechanisms

• Endothelial dysfunction: impaired nitric‑oxide production leads to inadequate vasodilation.
• Structural remodeling: thickening of the micro‑vessel walls, fibrosis, or rarefaction (reduction in vessel density).
• Coronary vasospasm: transient, intense constriction of micro‑vessels.
• Inflammation and oxidative stress: systemic inflammation can impair microvascular function.
• Abnormal pain perception: heightened sensitivity of cardiac nerve fibers (central sensitization).

Risk Factors

• Female sex (particularly post‑menopausal).
• Hypertension.
• Hyperlipidemia.
• Insulin resistance or type 2 diabetes.
• Obesity (BMI ≥ 30 kg/m²).
• Smoking (current or former).
• Physical inactivity.
• Autoimmune disorders (e.g., systemic lupus erythematosus, rheumatoid arthritis).
• History of migraine, Raynaud’s phenomenon, or peripheral artery disease – conditions that suggest systemic microvascular disease.

Diagnosis

Diagnosing microvascular angina is a process of exclusion: first rule out obstructive CAD, then demonstrate impaired microvascular function.

Step‑by‑Step Diagnostic Approach

1. Clinical evaluation: detailed history, physical exam, and assessment of cardiovascular risk.
2. Baseline ECG and cardiac biomarkers: to exclude acute coronary syndrome.
3. Stress testing:
   • Exercise ECG (if the baseline ECG is interpretable).
   • Stress myocardial perfusion imaging (SPECT, PET) or stress cardiac MRI – may show ischemia despite normal epicardial arteries.
4. Coronary angiography (invasive or CT): confirms absence of ≥ 50 % stenosis in major coronary arteries.
5. Microvascular function testing:
   • Coronary Flow Reserve (CFR) measured with Doppler wire or thermodilution during invasive angiography; CFR < 2.0 suggests dysfunction.
   • Index of Microcirculatory Resistance (IMR) – a quantitative measure obtained invasively; IMR > 25 U indicates abnormal microvascular resistance.
   • Non‑invasive alternatives: PET myocardial blood flow, cardiac MRI perfusion mapping, or transthoracic Doppler echocardiography of the left anterior descending artery.
6. Exclusion of other causes: esophageal spasm, gastroesophageal reflux, pericarditis, musculoskeletal pain.

Guidelines from the American College of Cardiology (ACC) and the European Society of Cardiology (ESC) recommend a combination of functional testing and invasive assessment when the diagnosis remains uncertain.²

Treatment Options

Management focuses on relieving symptoms, improving microvascular function, and reducing cardiovascular risk.

Pharmacologic Therapies

• Beta‑blockers: Reduce heart rate and myocardial oxygen demand; first‑line for many patients.
• Calcium‑channel blockers (CCBs): Particularly useful if vasospasm is suspected (e.g., amlodipine, diltiazem).
• Nitrates: Provide short‑term relief but often less effective than for obstructive CAD.
• Ranolazine: Improves myocardial metabolism and has been shown to reduce angina frequency in MVA trials.³
• ACE inhibitors/ARBs: Help improve endothelial function and are recommended for patients with hypertension or diabetes.
• Statins: Lower LDL cholesterol and exert pleiotropic effects that enhance endothelial health.
• Aspirin: Low‑dose (81 mg) for primary prevention in patients with elevated cardiovascular risk, unless contraindicated.
• Antidepressants (SSRIs or SNRIs): May be added when chronic pain or anxiety worsens angina perception.

Procedural & Interventional Options

• Enhanced External Counter‑Pulsation (EECP): Non‑invasive pneumatic cuffs that augment diastolic flow; modest benefit in selected patients.
• Spinal cord stimulation: Reserved for refractory cases; limited data.
• Coronary microvascular revascularization: No established percutaneous therapy because the problem lies in vessel function, not a focal lesion.

Lifestyle Modifications

• Regular aerobic exercise – aim for 150 min/week of moderate‑intensity activity (e.g., brisk walking, cycling). Exercise improves endothelial nitric‑oxide production.
• Heart‑healthy diet: Mediterranean or DASH patterns rich in fruits, vegetables, whole grains, fish, nuts, and olive oil.
• Weight management – maintain BMI < 25 kg/m².
• Smoking cessation – nicotine worsens endothelial dysfunction.
• Stress reduction: mindfulness‑based stress reduction (MBSR), yoga, or CBT.
• Adequate sleep (7‑9 hours) and limiting alcohol to ≤ 1 drink/day (women) or ≤ 2 drinks/day (men).

Living with Microvascular Angina

Living with MVA requires a proactive, long‑term approach.

Daily Management Tips

• Track symptoms: Use a simple diary (date, activity, pain intensity 0‑10, relief measures). This helps the physician tailor therapy.
• Medication adherence: Set alarms or use pillboxes.
• Gradual exercise plan: Start with low‑intensity sessions and increase duration under physician guidance.
• Warm‑up before exertion: A 5‑10 minute warm‑up can blunt abrupt microvascular demand spikes.
• Know your nitroglycerin: Carry a sublingual tablet for breakthrough pain; if it doesn’t relieve discomfort after 5 minutes, seek medical attention.
• Manage comorbidities: Keep blood pressure, cholesterol, and glucose within target ranges.
• Psychological support: Join support groups or counseling; anxiety can amplify chest pain.

Follow‑up Schedule

Most patients are seen every 3–6 months initially, then annually if stable. Repeat stress imaging may be ordered if symptoms change or worsen.

Prevention

Because many risk factors overlap with generic cardiovascular disease, primary prevention strategies are similar.

• Control blood pressure < 130/80 mmHg (or individualized target).
• Maintain LDL‑C < 70 mg/dL for high‑risk individuals.
• Engage in regular physical activity and avoid prolonged sedentary periods.
• Adopt a Mediterranean dietary pattern – rich in omega‑3 fatty acids, polyphenols, and antioxidants.
• Quit smoking using nicotine replacement therapy or prescription medications (varenicline, bupropion).
• Manage stress with relaxation techniques, adequate sleep, and mental‑health resources.

Complications

If untreated or inadequately managed, microvascular angina may lead to:

• Reduced quality of life: Persistent chest pain limits daily activities and can cause depression.
• Progression to heart failure with preserved ejection fraction (HFpEF): Microvascular dysfunction is a recognized contributor to HFpEF, especially in women.
• Increased risk of major adverse cardiovascular events (MACE): Although absolute risk is lower than obstructive CAD, longitudinal studies show higher rates of myocardial infarction and stroke compared with asymptomatic controls.⁴
• Psychological sequelae: Chronic pain may lead to anxiety, depression, and decreased adherence to therapy.

When to Seek Emergency Care

---

References

1. Mayo Clinic – Microvascular Angina
2. ACC Clinical Guidance on Microvascular Dysfunction (2020)
3. Ranolazine trial in microvascular angina, NEJM, 2013
4. Cleveland Clinic – Microvascular Angina Overview
5. World Health Organization. Cardiovascular disease fact sheets. Updated 2023.